Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antibiotic prophylaxis-Hamilton Health Sciences Corporation-febrile urinary tract infection
- Development stage
- Unknown
- Lead developer
- Hamilton Health Sciences
- Modality
- Small Molecules
01
Overview
antibiotic prophylaxis-Hamilton Health Sciences Corporation-febrile urinary tract infection refers to a specific clinical intervention protocol evaluated in the APPrUV (Antibiotic Prophylaxis in VCUG) pilot randomized controlled trial. Sponsored by Hamilton Health Sciences Corporation, this regimen involves the administration of a single oral dose of either trimethoprim (for infants younger than 2 months) or trimethoprim-sulfamethoxazole (for infants aged 2 months to 3 years) prior to a voiding cystourethrogram (VCUG) procedure. The primary objective is to reduce the incidence of post-procedure febrile urinary tract infections (fUTI), a known complication of VCUG. Trimethoprim acts by binding to and inhibiting the enzyme dihydrofolate reductase, while sulfamethoxazole inhibits dihydropteroate synthase; together, they block successive steps in the bacterial synthesis of essential nucleic acids and proteins.
- Other names
- Antibiotic Prophylaxis in VCUG
02
Targets
DHPS (Dihydropteroate synthase)Nucleotide synth (Nucleotide synthesis enzymes)
Beyond the preview
Go deeper on antibiotic prophylaxis-Hamilton Health Sciences Corporation-febrile urinary tract infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antibiotic prophylaxis-Hamilton Health Sciences Corporation-febrile urinary tract infection.